Related Experiment Video
Updated: Jul 7, 2025
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
Exploring the complexities of pain phenotypes: OMERACT 2023 chronic pain working group workshop
Tim Pickles1, Mary Cowern2, Robin Christensen3
1Centre for Trials Research, Cardiff University, Cardiff, UK.
Objective:
To educate and discuss pain mechanisms (nociceptive, neuropathic, nociplastic) illuminating its possible impact when measuring different outcomes, which may modify, confound and potentially bias the outcome measures applied across various aspects of Rheumatic Musculoskeletal Diseases (RMDs) clinical trials.
Methods:
In the plenary presentations, PM lectured on different pain mechanisms and impact on disease activity assessment. Data from two data sets of RMDs patients, which assessed the prevalence and impact of nociplastic pain were presented and reviewed. Audience breakout group sessions and polling were conducted.
Results:
Mixed pain etiologies may differentially influence disease activity assessment and therapeutic decision-making. Polling demonstrated a consensus on the need to assess different types of pain as a phenotype, as it constitutes an important contextual factor (a variable that is not an outcome of the trial, but needs to be recognized [and measured] to understand the study results), and to standardize across RMDs.
Conclusion:
There is need for a standardized pain measure that can differentiate underlying pain mechanisms.
